Cholestasis in Neonates and Infants

Neonatology: Questions and Controversies Series Gastroenterology and Nutrition

Volumn , Issue , 2008, Pages 135-162

  Davis, Michael K ^a   Andres, Joel M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942577324     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3160-4.10018-5     Document Type: Chapter

References (192)

1. Silveira TR, Salzano FM, Howard ER, et al. Congenital structural abnormalities in biliary atresia: evidence for etiopathogenic heterogeneity and therapeutic implications. Acta Paediatr Scand 1991, 80(12):1192-1199.
2. Haber BA, Russo P Biliary atresia. Gastroenterol Clin North Am 2003, 32(3):891-911.
3. Chen L, Goryachev A, Sun J, et al. Altered expression of genes involved in hepatic morphogenesis and fibrogenesis are identified by cDNA microarray analysis in biliary atresia. Hepatology 2003, 38(3):567-576.
4. Zhang DY, Sabla G, Shivakumar P, et al. Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. Hepatology 2004, 39(4):954-962.
5. Moyer V, Freese DK Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004, 39(2):115-128.. Erratum in: J Pediatr Gastroenterol Nutr 2004; 39(3):306.
6. Li MK, Crawford JM The pathology of cholestasis. Semin Liver Dis 2004, 24(1):21-42.
7. Kobayashi H, Stringer MD Biliary atresia. Semin Neonatol 2003, 8(5):383-391.
8. Iinuma Y, Narisawa R, Iwafuchi M, et al. The role of endoscopic retrograde cholangiopancreatography in infants with cholestasis. J Pediatr Surg 2000, 35(4):545-549.
9. Senyuz OF, Yesildag E, Emir H, et al. Diagnostic laparoscopy in prolonged jaundice. J Pediatr Surg 2001, 36(3):463-465.
10. Okazaki T, Miyano G, Yamataka A, et al. Diagnostic laparoscopy-assisted cholangiography in infants with prolonged jaundice. Pediatr Surg Int 2006, 22(2):140-143.. Epub 2005 Dec 8.
11. Lykavieris P, Chardot C, Sokhn M, et al. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 2005, 41(2):366-371.
12. Bielamowicz A, Weitzman JJ, Alshak NS, et al. Successful late Kasai portoenterostomy. J Pediatr Gastroenterol Nutr 1992, 14(2):232-236.
13. Barshes NR, Lee TC, Balkrishnan R, et al. Orthotopic liver transplantation for biliary atresia: the U.S. experience. Liver Transpl 2005, 11(10):1193-2000.
14. Chen CL, Concejero A, Wang CC, et al. Living donor liver transplantation for biliary atresia: a single-center experience with first 100 cases. Am J Transplant 2006, 6(11):2672-2679.
15. Tiao G, Ryckman FC Pediatric liver transplantation. Clin Liver Dis 2006, 10(1):169-197,. vii.
16. Bucuvalas JC, Ryckman FC Long-term outcome after liver transplantation in children. Pediatr Transplant 2002, 6(1):30-36.
17. Alagille D, Odievre M, Gautier M, et al. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 1975, 86(1):63-71.
18. Deprettere A, Portmann B, Mowat AP Syndromic paucity of the intrahepatic bile ducts: diagnostic difficulty; severe morbidity throughout early childhood. J Pediatr Gastroenterol Nutr 1987 Nov-Dec, 6(6):865-871.
19. Sharp HL The current status of alpha-1-antityrpsin, a protease inhibitor, in gastrointestinal disease. Gastroenterology 1976, 70(4):611-621.
20. Tzakis AG, Reyes J, Tepetes K, et al. Liver transplantation for Alagille's syndrome. Arch Surg 1993, 128(3):337-339.
21. Sherman P, Kolster E, Davies C, et al. Choledochal cysts: heterogeneity of clinical presentation. J Pediatr, Gastroenterol Nutr 1986, 5(6):867-872.
22. Ando K, Miyano T, Kohno S, et al. Spontaneous perforation of choledochal cyst: a study of 13 cases. Eur J Pediatr Surg 1998, 8(1):23-25.
23. Ikeda S, Sera Y, Akagi M Serial ultrasonic examination to differentiate biliary atresia from neonatal hepatitis--special reference to changes in size of the gallbladder. Eur J Pediatr 1989, 148(5):396-400.
24. Sharp HL The current status of alpha-1-antityrpsin, a protease inhibitor, in gastrointestinal disease. Gastroenterology 1976, 70(4):611-621.
25. Hood JM, Koep LJ, Peters RL, et al. Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. N Engl J Med 1980, 302(5):272-275.
26. Kaufman SS, Gondolesi GE, Fishbein TM Parenteral nutrition associated liver disease. Semin Neonatol 2003, 8(5):375-381.
27. Arias IM Inheritable and congenital hyperbilirubinemia. Models for the study of drug metabolism. N Engl J Med 1971, 285(25):1416-1421.
28. Kartenbeck J, Leuschner U, Mayer R, et al. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996, 23(5):1061-1066.
29. Adachi Y, Yamamoto T Partial defect in hepatic glutathione S-transferase activity in a case of Rotor's syndrome. Gastroenterol Jpn 1987, 22(1):34-38.
30. Suita S, Arima T, Ishii K, et al. Fate of infants with neonatal hepatitis: pediatric surgeons' dilemma. J Pediatr Surg 1992, 27(6):696-699.
31. Franson TR, Hierholzer WJ, LaBrecque DR Frequency and characteristics of hyperbilirubinemia associated with bacteremia. Rev Infect Dis 1985, 7(1):1-9.
32. Garcia FJ, Nager AL Jaundice as an early diagnostic sign of urinary tract infection in infancy. Pediatrics 2002, 109(5):846-851.
33. Gamble JR, Vadas MA Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988, 242(4875):97-99.
34. Keller GA, West MA, Harty JT, et al. Modulation of hepatocyte protein synthesis by endotoxin-activated Kupffer cells. Ann Surg 1985, 201(4):436-443.
35. Keppler D, Hagmann W, Rapp S, et al. The relation of leukotrienes to liver injury. Hepatology 1985, 5(5):883-891.
36. Becroft DM, Farmer K, Seddon RJ, et al. Epidemic listeriosis in the newborn. Br Med J 1971, 3(5777):747-751.
37. Alpert G, Plotkin SA A practical guide to the diagnosis of congenital infections in the newborn infant. Pediatr Clin North Am 1986, 33(3):465-479.
38. Montoya JG, Liesenfeld O Toxoplasmosis. Lancet 2004, 363(9425):1965-1976.
39. Watkins JB, Sunaryo FP, Berezin SH Hepatic manifestations of congenital and perinatal disease. Clin Perinatol 1981, 8(3):467-480.
40. Remington JS, Desmonts G: Toxoplasmosis. Infectious diseases of the fetus and newborn 2006, 984. Elsevier Saunders, Philadelphia. J.S. Remington, J.O. Klein (Eds.).
41. Naot Y, Desmonts G, Remington JS IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr 1981, 98(1):32-36.
42. Romand S, Wallon M, Franck J, et al. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 2001, 97(2):296-300.
43. Buxton D, Thomson K, Maley S, et al. Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec 1991, 129(5):89-93.
44. Ismael AB, Dimier-Poisson I, Lebrun M, et al. Mic1-3 Knockout of Toxoplasma gondii is a Successful Vaccine against Chronic and Congenital Toxoplasmosis in Mice. J Infect Dis 2006, 194(8):1176-1183.
45. Watkins JB, Sunaryo FP, Berezin SH Hepatic manifestations of congenital and perinatal disease. Clin Perinatol 1981, 8(3):467-480.
46. Darville T Syphilis. Pediatr Rev 1999, 20(5):160-164.
47. Long WA, Ulshen MH, Lawson EE Clinical manifestations of congenital syphilitic hepatitis: implications for pathogenesis. J Pediatr Gastroenterol Nutr 1984, 3(4):551-555.
48. Pound MW, May DB Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005, 30(3):291-295.
49. Banatvala JE, Brown DW Rubella. Lancet 2004, 363(9415):1127-1137.
50. Meegan JM, Evans BK, Horstmann DM Comparison of the latex agglutination test with the hemagglutination inhibition test, enzyme-linked immunosorbent assay, and neutralization test for detection of antibodies to rubella virus. J Clin Microbiol 1982, 16(4):644-649.
51. Griffiths PD Cytomegalovirus and the liver. Semin Liver Dis 1984, 4(4):307-313.
52. Stagno S, Whitley RJ Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 1985, 313(20):1270-1274.
53. Ahlfors K, Ivarsson SA, Harris S, et al. Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Scand J Infect Dis 1984, 16(2):129-137.
54. Ghishan FK, Greene HL, Halter S, et al. Noncirrhotic portal hypertension in congenital cytomegalovirus infection. Hepatology 1984, 4(4):684-686.
55. Ahlfors K, Ivarsson SA, Harris S, et al. Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Scand J Infect Dis 1984, 16(2):129-137.
56. Bale JF, Blackman JA, Sato Y Outcome in children with symptomatic congenital cytomegalovirus infection. J Child Neurol 1990, 5(2):131-136.
57. Jacobson MA, Cello JP, Sande MA Cholestasis and disseminated cytomegalovirus disease in patients with the acquired immunodeficiency syndrome. Am J Med 1988, 84(2):218-224.
58. Wolff MA, Rand KH, Houck HJ, et al. Relationship of the polymerase chain reaction for cytomegalovirus to the development of hepatitis in liver transplant recipients. Transplantation 1993, 56(3):572-576.
59. Ross SA, Boppana SB Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis 2005, 16(1):44-49.
60. Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987, 257(22):3082-3087.
61. Schleiss MR Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis 2005, 16(1):50-59.
62. Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med 1987, 317(20):1246-1251.
63. Kimberlin DW Herpes simplex virus infections in neonates and early childhood. Semin Pediatr Infect Dis 2005, 16(4):271-281.
64. Wong VC, Lee AK, Ip HM Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. Br J Obstet Gynaecol 1980, 87(11):958-965.
65. Tong MJ, Thursby M, Rakela J, et al. Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology 1981, 80(5 pt 1):999-1004.
66. Mulligan MJ, Stiehm ER Neonatal hepatitis B infection: clinical and immunologic considerations. J Perinatol 1994, 14(1):2-9.
67. Delaplane D, Yogev R, Crussi F, et al. Fatal hepatitis B in early infancy: the importance of identifying HBsAg-positive pregnant women and providing immunoprophylaxis to their newborns. Pediatrics 1983, 72(2):176-180.
68. Watkins JB, Sunaryo FP, Berezin SH Hepatic manifestations of congenital and perinatal disease. Clin Perinatol 1981, 8(3):467-480.
69. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987, 257(19):2612-2616.
70. Stevens CE Viral hepatitis in pregnancy: Problems for the physician dealing with the infant. Pediatr Rev 1980, 2:121.
71. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2(8256):1129-1133.
72. Snydman DR Hepatitis in pregnancy. N Engl J Med 1985, 313(22):1398-1401.
73. West DJ, Calandra GB, Ellis RW Vaccination of infants and children against hepatitis B. Pediatr Clin North Am 1990, 37(3):585-601.
74. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2(8359):1099-1102.
75. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984, 1(8383):921-926.
76. American Academy of Pediatrics. Childhood Immunization Support Program (CISP): 2006 Childhood Immunization Schedule and Catch-up Schedule. /. Accessed October 2006. http://www.cispimmunize.org.
77. Slowik MK, Jhaveri R Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005, 16(4):296-305.
78. Hepatitis A. Redbook: 2006 Report of the Committee on Infectious Diseases 2006, 326-335. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village, IL. 27th. L.K. Pickering, C.J. Baker, S.S. Long, J.A. McMillan (Eds.).
79. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990, 264(17):2231-2235.
80. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of HCV in a cohort of 2447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001, 33:570-575.
81. Yeung LTF, King SM, Roberts EA Mother-to-infant transmission of hepatitis C virus. Hepatology 2001, 34:223-229.
82. Dore GJ, Kaldor JM, McCaughan GW Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997, 315:333-337.
83. A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005, 192:1872-1879. European Paediatric Hepatitis C.
84. Hepatitis C. Redbook: 2006 Report of the Committee on Infectious Diseases 2006, 355-359. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village, IL. 27th. L.K. Pickering, C.J. Baker, S.S. Long, J.A. McMillan (Eds.).
85. Zanetti AR, Ferroni P, Magliano EM, et al. Perinatal transmission of the hepatitis B virus and of the HBV-associated delta agent from mothers to offspring in northern Italy. J Med Virol 1982, 9(2):139-148.
86. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220(4599):868-871.
87. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224(4648):500-503.
88. Shetty AK Perinatally acquired HIV-1 infection: prevention and evaluation of HIV-exposed infants. Semin Pediatr Infect Dis 2005, 16(4):282-295.
89. Rogers MF, Thomas PA, Starcher ET, et al. Acquired immunodeficiency syndrome in children: report of the Centers for Disease Control National Surveillance, 1982 to 1985. Pediatrics 1987, 79(6):1008-1014.
90. Shannon KM, Ammann AJ Acquired immune deficiency syndrome in childhood. J Pediatr 1985, 106(2):332-342.
91. Pahwa S, Kaplan M, Fikrig S, et al. Spectrum of human T-cell lymphotropic virus type III infection in children. Recognition of symptomatic, asymptomatic, and seronegative patients. JAMA 1986, 255(17):2299-2305.
92. Rubinstein A, Bernstein L The epidemiology of pediatric acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1986, 40(1):115-121.
93. Ziegler JB, Cooper DA, Johnson RO, et al. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1985, 1(8434):896-898.
94. Rogers MF AIDS in children: a review of the clinical, epidemiologic and public health aspects. Pediatr Infect Dis 1985, 4(3):230-236.
95. Oleske J, Minnefor A, Cooper R, et al. Immune deficiency syndrome in children. JAMA 1983, 249(17):2345-2349.
96. Scott GB, Buck BE, Leterman JG, et al. Acquired immunodeficiency syndrome in infants. N Engl J Med 1984, 310(2):76-81.
97. Ammann AJ, Shannon KM Recognition of acquired immune deficiency syndrome (AIDS) in children. Pediatr Rev 1985, 7:101.
98. Persaud D, Bangaru B, Greco MA, et al. Cholestatic hepatitis in children infected with the human immunodeficiency virus. Pediatr Infect Dis J 1993, 12(6):492-498.
99. Duffy LF, Daum F, Kahn E, et al. Hepatitis in children with acquired immune deficiency syndrome. Histopathologic and immunocytologic features. Gastroenterology 1986, 90(1):173-181.
100. Sacks SL, Freeman HJ Cytomegalovirus hepatitis: evidence for direct hepatic viral infection using monoclonal antibodies. Gastroenterology 1984, 86(2):346-350.
101. Finegold MJ, Carpenter RJ Obliterative cholangitis due to cytomegalovirus: a possible precursor of paucity of intrahepatic bile ducts. Hum Pathol 1982, 13(7):662-665.
102. Pyun KH, Ochs HD, Dufford MT, et al. Perinatal infection with human immunodeficiency virus. Specific antibody responses by the neonate. N Engl J Med 1987, 317(10):611-614.
103. Benjamin DK, Miller WC Rational testing of the HIV-exposed infant. Pediatrics 2001, 108(1):E3.
104. Human Immunodeficiency Virus Infection. Redbook: 2006 Report of the Committee on Infectious Diseases 2006, 378-401. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village, IL. 27th. L.K. Pickering, C.J. Baker, S.S. Long, J.A. McMillan, S.A. Fiscas (Eds.).
105. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331(18):1173-1180.
106. Lambert JS HIV vaccines in infants and children. Paediatr Drugs 2005, 7(5):267-276.
107. Modlin JF Fatal echovirus 11 disease in premature neonates. Pediatrics 1980, 66(5):775-780.
108. Mostoufizadeh M, Lack EE, Gang DL, et al. Postmortem manifestations of echovirus 11 sepsis in five newborn infants. Hum Pathol 1983, 14(9):818-823.
109. Gillam GL, Stokes KB, McLellan J, et al. Fulminant hepatic failure with intractable ascites due to an echovirus 11 infection successfully managed with a peritoneo-venous (LeVeen) shunt. J Pediatr Gastroenterol Nutr 1986, 5(3):476-480.
110. Chuang E, Maller ES, Hoffman MA, et al. Successful treatment of fulminant echovirus 11 infection in a neonate by orthotopic liver transplantation. J Pediatr Gastroenterol Nutr 1993, 17(2):211-214.
111. Cheng LL, Ng PC, Chan PK, et al. Probable intrafamilial transmission of coxsackievirus b3 with vertical transmission, severe early-onset neonatal hepatitis, and prolonged viral RNA shedding. Pediatrics 2006, 118(3):e929-e933.. Epub 2006 Aug 14.
112. Bryant PA, Tingay D, Dargaville PA, et al. Neonatal coxsackie B virus infection - a treatable disease?. Eur J Pediatr 2004, 163(4-5):223-228.. Epub 2004 Feb 18.
113. Aradottir E, Alonso EM, Shulman ST Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr Infect Dis J 2001, 20(4):457-459.
114. Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995, 20(5):1201-1206.
115. Maeda H, Shimokawa H, Satoh S, et al. Nonimmunologic hydrops fetalis resulting from intrauterine human parvovirus B-19 infection: report of two cases. Obstet Gynecol 1988, 72(3 Pt 2):482-485.
116. de Jong EP, de Haan TR, Kroes AC, et al. Parvovirus B19 infection in pregnancy. J Clin Virol 2006, 36(1):1-7.. Epub 2006 Feb 20.
117. Mark Y, Rogers BB, Oyer CE Diagnosis and incidence of fetal parvovirus infection in an autopsy series: II. DNA amplification. Pediatr Pathol 1993, 13(3):381-386.
118. Abzug MJ, Levin MJ Neonatal adenovirus infection: four patients and review of the literature. Pediatrics 1991, 87(6):890-896.
119. Krilov LR, Rubin LG, Frogel M, et al. Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states. Rev Infect Dis 1990, 12(2):303-307.
120. Law RH, Zhang Q, McGowan S, Buckle AM, et al. An overview of the serpin superfamily. Genome Biol 2006, 7(5):216.
121. Byth BC, Billingsley GD, Cox DW Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency. Am J Hum Genet 1994, 55(1):126-133.
122. Crowther DC, Belorgey D, Miranda E, et al. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet 2004, 12(3):167-172.
123. Silverman EK, Miletich JP, Pierce JA, et al. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989, 140(4):961-966.
124. Brantly M, Courtney M, Crystal RG Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. Science 1988, 242(4886):1700-1702.
125. Carrell RW, Lomas DA Alpha1-antitrypsin deficiency - a model for conformational diseases. N Engl J Med 2002, 346(1):45-53.
126. Sveger T Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976, 294(24):1316-1321.
127. Wu Y, Whitman I, Molmenti E, et al. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci USA 1994, 91(19):9014-9018.
128. Qu D, Teckman JH, Omura S, Perlmutter DH Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996, 271(37):22791-22795.
129. Doherty DG, Donaldson PT, Whitehouse DB, et al. HLA phenotypes and gene polymorphisms in juvenile liver disease associated with alpha 1-antitrypsin deficiency. Hepatology 1990, 12(2):218-223.
130. Juvelekian GS, Stoller JK Augmentation therapy for alpha(1)-antitrypsin deficiency. Drugs 2004, 64(16):1743-1756.
131. Lu Y, Choi YK, Campbell-Thompson M, et al. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J Gene Med 2006, 8(6):730-735.
132. Ghishan FK, Gray GF, Greene HL Alpha 1-antitrypsin deficiency presenting with ascites and cirrhosis in the neonatal period. Gastroenterology 1983, 85(2):435-438.
133. Hinds R, Hadchouel A, Shanmugham NP, et al. Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin deficiency-related liver disease. J Pediatr Gastroenterol Nutr 2006, 43(1):136-138.
134. Dry PJ Rapid detection of alpha-1-antitrypsin deficiency by analysis of a PCR-induced TaqI restriction site. Hum Genet 1991, 87(6):742-744.
135. Rowe SM, Miller S, Sorscher EJ Cystic fibrosis. N Engl J Med 2005, 352(19):1992-2001.
136. Colombo C, Russo MC, Zazzeron L, Romano G Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006, 43(Suppl 1):S49-S55.
137. Kinnman N, Lindblad A, Housset C, et al. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology 2000, 32(2):334-340.
138. Paumgartner G, Beuers U Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36(3):525-531.
139. Grubman SA, Fang SL, Mulberg AE, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 1995, 108(2):584-592.
140. Yang Y, Raper SE, Cohn JA, et al. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 1993, 90(10):4601-4605.
141. Grompe M, St-Louis M, Demers SI, et al. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 1994, 331:353.
142. Awata H, Endo F, Tanoue A, et al. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I. Biochim Biophys Acta 1994, 1226(2):168-172.
143. St-Louis M, Leclerc B, Laine J, et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet 1994, 3:69.
144. Phaneuf D, Lambert M, Laframboise R, et al. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 1992, 90(4):1185-1192.
145. Held PK, Olivares EC, Aguilar CP, et al. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 2005, 11(3):399-408.
146. Montini E, Held PK, Noll M, et al. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 2002, 6(6):759-769.
147. Phaneuf D, Hadchouel M, Tanguay RM, et al. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer. Biochem Biophys Res Commun 1995, 208(3):957-963.
148. McKiernan PJ Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006, 66(6):743-750.
149. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 340(8823):813-817.
150. Holme E, Lindstedt S Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000, 4(4):805-814.
151. Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999, 158(Suppl 2):S49-S54.
152. Buyukpamukcu M, Varan A, Haberal M, et al. The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: clinical and laboratory findings of five cases. Pediatr Transplant 2006, 10(4):517-520.
153. Freese DK, Tuchman M, Schwarzenberg SJ, et al. Early liver transplantation is indicated for tyrosinemia type I. J Pediatr Gastroenterol Nutr 1991, 13(1):10-15.
154. Luijerink MC, Jacobs SM, van Beurden EA, et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol 2003, 39(6):901-909.
155. Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999, 158(Suppl 2):S49-S54.
156. Tanguay RM, Valet JP, Lescault A, et al. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 1990, 47(2):308-316.
157. van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994, 20(5):1187-1191.
158. Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990, 322(7):432-437.
159. Wyss PA, Boynton S, Chu J, et al. Tissue distribution of succinylacetone in the rat in vivo: a possible basis for neurotoxicity in hereditary infantile tyrosinemia. Biochim Biophys Acta 1993, 1182(3):323-328.
160. Russo PA, Mitchell GA, Tanguay RM Tyrosinemia: a review. Pediatr Dev Pathol 2001, 4(3):212-221.
161. Whitington PF Fetal and infantile hemochromatosis. Hepatology 2006, 43(4):654-660.
162. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408.
163. Kelly AL, Lunt PW, Rodrigues F, et al. Classification and genetic features of neonatal haemochromatosis: a study of 27 affected pedigrees and molecular analysis of genes implicated in iron metabolism. J Med Genet 2001, 38(9):599-610.
164. Dalhoj J, Kiaer H, Wiggers P, et al. Iron storage disease in parents and sibs of infants with neonatal hemochromatosis: 30-year follow-up. Am J Med Genet 1990, 37(3):342-345.
165. Whitington PF, Hibbard JU High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 2004, 364(9446):1690-1698.
166. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood 2005, 105(10):4103-4105.
167. Wisser J, Schreiner M, Diem H, et al. Neonatal hemochromatosis: a rare cause of nonimmune hydrops fetalis and fetal anemia. Fetal Diagn Ther 1993, 8(4):273-278.
168. Kershisnik MM, Knisely AS, Sun CC, et al. Cytomegalovirus infection, fetal liver disease, and neonatal hemochromatosis. Hum Pathol 1992, 23(9):1075-1080.
169. Bove KE, Wong R, Kagen H, et al. Exogenous iron overload in perinatal hemochromatosis: a case report. Pediatr Pathol 1991, 11(3):389-397.
170. Shneider BL, Setchell KD, Whitington PF, et al. Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr 1994, 124(2):234-238.
171. Schoenlebe J, Buyon JP, Zitelli BJ, et al. Neonatal hemochromatosis associated with maternal autoantibodies against Ro/SS-A and La/SS-B ribonucleoproteins. Am J Dis Child 1993, 147(10):1072-1075.
172. Murray KF, Kowdley KV Neonatal hemochromatosis. Pediatrics 2001, 108(4):960-964.
173. Ramm GA, Ruddell RG Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005, 25(4):433-449.
174. Jonas MM, Kaweblum YA, Fojaco R Neonatal hemochromatosis: failure of deferoxamine therapy. J Pediatr Gastroenterol Nutr 1987, 6(6):984-988.
175. Rodrigues F, Kallas M, Nash R, et al. Neonatal hemochromatosis - medical treatment vs. transplantation: the king's experience. Liver Transpl 2005, 11(11):1417-1424.
176. Flynn DM, Mohan N, McKiernan P, et al. Progress in treatment and outcome for children with neonatal haemochromatosis. Arch Dis Child Fetal Neonatal Ed 2003, 88(2):F124-F127.
177. Sigurdsson L, Reyes J, Kocoshis SA, et al. Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies. J Pediatr Gastroenterol Nutr 1998, 26(1):85-89.
178. Bove KE, Heubi JE, Balistreri WF, et al. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol 2004, 7(4):315-334.
179. Siafakas CG, Jonas MM, Perez-Atayde AR Abnormal bile acid metabolism and neonatal hemochromatosis: a subset with poor prognosis. J Pediatr Gastroenterol Nutr 1997, 25(3):321-326.
180. Cheng JB, Jacquemin E, Gerhardt M, et al. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J Clin Endocrinol Metab 2003, 88(4):1833-1841.
181. Setchell KD, Heubi JE Defects in bile acid biosynthesis--diagnosis and treatment. J Pediatr Gastroenterol Nutr 2006, 43(Supp. 1):S17-S22.
182. Sokol RJ, Treem WR Mitochondria and childhood liver diseases. J Pediatr Gastroenterol Nutr 1999, 28(1):14-16.
183. Bioulac-Sage P, Parrot-Roulaud F, Mazat JP, et al. Fatal neonatal liver failure and mitochondrial cytopathy (oxidative phosphorylation deficiency): a light and electron microscopic study of the liver. Hepatology 1993, 18(4):839-846.
184. Sokal EM, Sokol R, Cormier V, et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999, 158(Supp. 2):S81-S84.
185. Trauner M, Meier PJ, Boyer JL Molecular regulation of hepatocellular transport systems in cholestasis. J Hepatol 1999, 31(1):165-178.
186. Bull LN, van Eijk MJ, Pawlikowska L, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998, 18(3):219-224.
187. Shneider BL Genetic cholestasis syndromes. J Pediatr Gastroenterol Nutr 1999, 28(2):124-131.
188. Elferink RP, Groen AK The mechanism of biliary lipid secretion and its defects. Gastroenterol Clin North Am 1999, 28(1):59-74,. vi.
189. Balistreri WF Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997, 24(5):573-589.
190. Yerushalmi B, Sokol RJ, Narkewicz MR, et al. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29(4):442-447.
191. Sokol RJ, Guggenheim MA, Heubi JE, et al. Frequency and clinical progression of the vitamin E deficiency neurologic disorder in children with prolonged neonatal cholestasis. Am J Dis Child 1985, 139(12):1211-1215.
192. Sokol RJ, Heubi JE, Butler-Simon N, et al. Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-alpha-tocopheryl polyethylene glycol-1000 succinate. Gastroenterology 1987, 93(5):975-985.